RadNet prices 10⅜% senior notes due 2018

NewsGuard 100/100 Score

RadNet, Inc. (Nasdaq:RDNT), (the "Company"), a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 180 imaging centers, today announced the pricing of its offering of $200 million in aggregate principal amount of 10⅜% senior notes due 2018 (the "Notes") at an issue price of 98.680%. The Notes will be issued by the Company's wholly-owned subsidiary Radnet Management, Inc. (the "Issuer") and guaranteed jointly and severally on a senior basis by the Company and all of the Issuer's current and future wholly-owned domestic restricted subsidiaries.

Concurrently with the closing of this offering, which is expected to occur on April 6, 2010, the Issuer intends to terminate its existing senior secured credit facilities and enter into a new $285 million secured term loan and a new $100 million secured revolving credit facility, which is expected to be undrawn at closing.

The Company estimates that the net proceeds from the offering, together with the proceeds of borrowings under its new senior secured credit facilities, will be $485 million, before related fees and offering expenses. The Company intends to use the net proceeds to refinance its existing senior secured credit facilities, fund its previously announced acquisitions currently under letters of intent, increase the cash available on its balance sheet to more then $25 million and pay related fees and expenses.

The Notes were offered and sold in a private placement exempt from registration under the Securities Act to qualified institutional buyers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act").

SOURCE RadNet, Inc.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-driven mammography cuts workload by 33%, boosts breast cancer detection